Corcept Therapeutics Inc
CORT
Market Cap$7.43B
Close$
$192.88
175.3% upside
Current Fair Value
175.3% upsideUndervalued by 175.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.43 Billion |
|---|---|
| Enterprise Value | $7.36 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $1.35 |
| Beta | 0.18 |
| Outstanding Shares | 104,106,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 54.9 |
|---|---|
| PEG | -203.92 |
| Price to Sales | 11.68 |
| Price to Book Ratio | 11.68 |
| Enterprise Value to Revenue | 10.74 |
| Enterprise Value to EBIT | 66.39 |
| Enterprise Value to Net Income | 55 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...